story of the week
Naptumomab Estafenatox Plus Interferon Alpha for Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα Versus IFNα in Renal Cell Carcinoma: Final Analysis With Baseline Biomarker Subgroup and Trend Analysis
Clin. Cancer Res 2016 Feb 05;[EPub Ahead of Print], RE Hawkins, M Gore, Y Shparyk, V Bondar, O Gladkov, T Ganev, M Harza, S Polenkov, I Bondarenko, P Karlov, O Karyakin, R Khasanov, G Hedlund, G Forsberg, Ö Nordle, T EisenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.